Drug Profile
Bempedoic acid/ezetimibe - Esperion Therapeutics
Alternative Names: ETC-1002/ezetimibe; Ezetimibe/bempedoic acid; Ezetimibe/ETC-1002; NEXLIZET; NustendiLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Esperion Therapeutics
- Developer Daiichi Sankyo Europe; Esperion Therapeutics
- Class Antihyperlipidaemics; Azetidines; Dicarboxylic acids; Fatty acids; Fluorobenzenes; Propanols; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Cholesterol absorption inhibitors; Cholesterol synthesis inhibitors; NPC1L1 protein inhibitors; Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dyslipidaemias; Hypercholesterolaemia
- Preregistration Cardiovascular disorders
Most Recent Events
- 21 Mar 2024 Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion for bempedoic acid/ezetiibe in Cardiovascular disorders
- 07 Mar 2024 FDA assigns PDUFA action date of 31/03/2024 for Bempedoic acid/ezetimibe for Cardiovascular disorders
- 06 Mar 2024 Esperion Therapeutics has patent protection for bempedoic acid / ezetimibe combination tablet in combination with one or more statins and for methods of treating familial hypercholesterolemia in USA, prior to March 2024